ESPREsperion Therapeutics Inc.
ESPR
Esperion Therapeutics Inc.9,206
Mkt Cap
$808.25MVolume
7.43M52W High
$4.1852W Low
$0.6925PE Ratio
-14.99ESPR Fundamentals
Price
$3.14Prev Close
$3.14Open
$3.1450D MA
$2.53Beta
1.53Avg. Volume
7.79MEPS (Annual)
-$0.1091P/B
-2.55Rev/Employee
$1.37M$1,149.25
Compact View
Not available
Not available
Poll
Earnings Recap
• Reported GAAP EPS of -$0.10 up 52.38% YoY • Reported revenue of $80.1M up 23.25% YoY • Esperion Therapeutics expects continued operating losses and consistent research and development expenses in 2026, with selling, general and administrative expenses anticipated to increase slightly in 2026.
Bullish
Esperion Therapeutics achieved increased revenues and a reduced net loss, while strategically expanding its cardiovascular portfolio through the acquisition of Corstasis and its FDA-approved product Enbumyst.
Bearish
Esperion Therapeutics faces ongoing operating losses, a material weakness in internal control over financial reporting, and persistent ANDA litigation regarding its key products, posing significant financial and operational risks.